

VU Research Portal

Cerebrospinal fluid biomarkers in dementia with Lewy bodies

van Steenoven, I.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van Steenoven, I. (2020). *Cerebrospinal fluid biomarkers in dementia with Lewy bodies: towards a biological diagnosis*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl



PART 2

Novel CSF biomarkers in dementia with Lewy bodies



CHAPTER 6

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

Inger van Steenoven*, Marleen J.A. Koel-Simmelink*, Leonie J.M. Vergouw, Betty M. Tijms, Sander R. Piersma, Thang V. Pham, Claire Bridel, Gian-Luca Ferri, Cristina Cocco, Barbara Noli, Paul F. Worley, Mei-Fang Xiao, Desheng Xu, Patrick Oeckl, Markus Otto, Wiesje M. van der Flier, Frank Jan de Jong, Connie R. Jimenez, Afina W. Lemstra, and Charlotte E. Teunissen

* *shared first authorship*

Molecular Neurodegeneration, 2020

ABSTRACT

Background: Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers have been proven useful in Alzheimer's disease (AD) diagnosis. Here, we aimed to identify novel CSF biomarkers for DLB using a high-throughput proteomic approach.

Methods: We applied liquid chromatography/tandem mass spectrometry with label-free quantification to identify biomarker candidates to individual CSF samples from a well-characterized cohort comprising patients with DLB (n=20) and controls (n=20). Validation was performed using (1) the identical proteomic workflow in an independent cohort (n=30), (2) proteomic data from patients with related neurodegenerative diseases (n=149) and (3) orthogonal techniques in an extended cohort consisting of DLB patients and controls (n=76). Additionally, we utilized random forest analysis to identify the subset of candidate markers that best distinguished DLB from all other groups.

Results: In total, we identified 1995 proteins. In the discovery cohort, 69 proteins were differentially expressed in DLB compared to controls ($p < 0.05$). Independent cohort replication confirmed VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N as candidate biomarkers for DLB. The downregulation of the candidate biomarkers was somewhat more pronounced in DLB in comparison with related neurodegenerative diseases. Using random forest analysis, we identified a panel of VGF, SCG2 and PDYN to best differentiate between DLB and other clinical groups (accuracy: 0.82 (95%CI: 0.75-0.89)). Moreover, we confirmed the decrease of VGF and NPTX2 in DLB by ELISA and SRM methods. Low CSF levels of all biomarker candidates, except PCSK1N, were associated with more pronounced cognitive decline ($0.37 < r < 0.56$, all $p < 0.01$).

Conclusion: We identified and validated six novel CSF biomarkers for DLB. These biomarkers, particularly when used as a panel, show promise to improve diagnostic accuracy and strengthen the importance of synaptic dysfunction in the pathophysiology of DLB.

INTRODUCTION

Dementia with Lewy Bodies (DLB) is a common cause of dementia in the elderly, accounting for up to 20% of dementia cases.¹ Clinical hallmarks of DLB are cognitive decline accompanied by parkinsonism, visual hallucinations, fluctuating cognition and rapid eye movement (REM) sleep behavior disorder (RBD).² Diagnosis of DLB during life is based on clinical diagnostic consensus criteria,² but a definite diagnosis of DLB requires post-mortem defined presence of Lewy bodies and Lewy neurites diffusely distributed throughout the brain.^{2, 3} Diagnosing DLB during life is challenging due to highly variable clinical manifestation and overlap in signs, symptoms and pathology with both Alzheimer's disease (AD) and Parkinson's disease (PD). There is thus a strong need for biomarkers supporting accurate and timely diagnosis of DLB.

Cerebrospinal fluid (CSF) is the best matrix to identify novel biomarkers for central nervous system disorders, due to its direct contact with the brain parenchyma and mirroring biochemical alterations occurring within the brain.^{4, 5} CSF biomarkers have been proven useful in AD, where a typical CSF profile of decreased levels of amyloid- β 1-42 (A β 42) combined with increased levels of total and phosphorylated Tau (t-tau, p-tau) protein levels supports the diagnosis of AD.⁶ So far, no such diagnostic biomarkers are available for DLB. CSF biomarkers for α -synuclein seem promising,⁷⁻⁹ but are still not sensitive and specific enough to function as single diagnostic biomarkers.

Mass spectrometry-based proteomics has emerged as an useful approach for unbiased candidate biomarker discovery in biofluids.^{10, 11} So far, only few proteomic studies have been performed for DLB, albeit in small and clinically heterogeneous cohorts, and results have not yet been validated.¹²⁻¹⁴

Here, we aimed to identify novel candidate proteins in CSF of DLB patients in a relatively large, well-characterized discovery cohort (20 DLB patients and 20 controls) using a state-of-the-art mass spectrometry workflow. We next thoroughly validated the results by (1) the same proteomic workflow in an independent cohort (n=30), (2) comparison of identified biomarkers values in related neurodegenerative diseases (n=149) and (3) enzyme-linked immunosorbent assays (ELISA) and selected reaction monitoring (SRM) for the most represented candidate biomarkers in an extended cohort (n=76).

METHODS

Patient selection

DLB patients and controls enrolled in the current study were selected from the Amsterdam Dementia Cohort and the Erasmus Medical Center. All subjects underwent extensive clinical examination including physical and neurological examination, neuropsychological assessment, electroencephalogram, structural brain imaging and laboratory tests.¹⁵ Additional diagnostic tests, such as ¹²³I[FP-CIT] single photon emission computed tomography (DaT-SPECT) were performed by indication. Diagnoses were made by consensus in a multidisciplinary meeting according to standard diagnostic criteria. Probable DLB was diagnosed according to the 2005 clinical consensus criteria.¹⁶ All patients also fulfilled novel consensus criteria.² Controls were individuals who presented at the memory clinic with cognitive complaints, but no abnormalities on clinical or cognitive testing were observed and criteria for mild cognitive impairment, dementia or other medical conditions associated with cognitive complaints were not met. Furthermore, all controls had normal AD biomarker levels in CSF,¹⁷ and preserved normal cognitive function on neuropsychological testing for at least two years after first presentation at the memory clinic. The study was performed according to the ethical principles of the Declaration of Helsinki and was approved by the local ethics committees. Written informed consent was obtained from all subjects.

Phase 1: Discovery

Cohort 1

For the biomarker discovery phase, 20 DLB patients and age- and sex-matched controls were selected from the Amsterdam Dementia Cohort according to the criteria described above. In addition, DLB patients in cohort 1 fulfilled the following additional inclusion criteria: (1) DaT-SPECT scan showing presynaptic dopaminergic deficits and (2) normal AD biomarker levels in the CSF.¹⁷

Phase 2: Proteomics Validation

Cohort 2

A second cohort consisted of an independent set of 17 DLB patients and 13 age- and sex-matched controls selected from the Amsterdam Dementia Cohort (n=27) and the Erasmus Medical Center (n=3) was used for validation using an identical proteomics workflow. The DLB patients in cohort 2 had less stringent inclusion criteria, namely DLB patients were not selected on the basis of normal CSF AD biomarker levels and a DaT-SPECT scan was not required.

Phase 3: Validation of candidate biomarkers

Cohort 3A

For the validation of the identified candidate biomarkers in related neurodegenerative diseases, we analyzed proteomic data previously generated in 20 patients with AD and 20 patients with frontotemporal dementia (FTD) as part of a parallel study (PRODIA Memorabel Project). In addition, proteomic data from 109 PD patients were provided by the Fox Investigation for New Discovery of Biomarkers (“BioFIND”) database (<http://biofind.loni.usc.edu/>).¹⁸

Cohort 3B


A subset of the identified candidate biomarkers was validated by orthogonal analytical techniques in CSF samples from DLB patients and controls. Cohort 3B consisted of additional 48 DLB patients and 28 controls selected from the Amsterdam Dementia Cohort. Cohort 3B was not completely independent from cohort 1 and 2, such that 15 controls and 18 DLB patients were overlapping between cohort 3B and cohort 1 and 3 controls and 6 DLB patients were overlapping between cohort 3B and cohort 2. DLB patients in cohort 3B fulfilled similar inclusion criteria as DLB patients in cohort 2.

CSF sample collection and storage

In line with international biobanking guidelines¹⁹, CSF was obtained by lumbar puncture between the L3/L4, L4/L5 or L5/S1 intervertebral space using a 25-gauge needle and collected in 10 mL polypropylene tubes (Starstedt, Nümbrecht, Germany). Part of the CSF was used for basic CSF analysis, and levels of A β 42, t-tau and p-tau were measured with commercially ELISA's (Innotest[®], Fujirebio, Gent, Belgium). The remaining CSF was centrifuged at 1800g at 4°C for 10 min, aliquoted in polypropylene tubes of 0.5 mL and stored at -80°C¹⁹ until further analysis.

Biomarker discovery analysis and validation

The workflow for mass-spectrometry biomarker discovery analysis and validation is summarized in Figure 1.

Figure 1 | Graphical summary of the workflow used to identify novel CSF biomarkers for DLB

(A) Graphical summary of study workflow. In short, CSF samples from cohort 1 were evaluated using a high-throughput proteomic workflow. The CSF proteome from DLB patients was compared with that of cognitively normal individuals. Validation was performed in an independent validation cohort (cohort 2) using an identical proteomic workflow. Proteins that were significantly altered in abundance in both cohort 1 and cohort 2 were indicated as candidate biomarkers. Levels of the identified candidate biomarkers in DLB patients were compared with the levels of the identified candidate biomarkers as quantified with mass spectrometry in related neurodegenerative diseases (cohort 3A). For a subset of the candidate biomarkers validation was performed using orthogonal methods (ELISA and SRM) in cohort 3B. (B) Graphical summary of the proteomic workflow. We applied an in-depth proteomic workflow, including abundant protein depletion, protein fractionation prior to nanoLC-MS/MS analysis and label-free protein quantification on CSF samples from DLB patients and controls in cohort 1 and 2.

CSF sample preparation and gel electrophoresis

CSF samples were coded and analyzed in a blinded fashion. The depletion of the top-14 high abundant proteins, i.e. albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, α 2-macroglobulin, α 1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement C3 and transthyretin, was performed as previously reported.²⁰ Depleted CSF was further concentrated using 3kDA filters (Millipore, Billerica, CA, USA) prior to loading the whole depleted CSF fraction on 1-D gradient gels from Invitrogen (Carlsbad, CA, USA; NuPAGE 4-12% Bis-Tris gel., 1.5mm x 10 wells). SDS-PAGE gels were stained overnight with Coomassie brilliant blue R250 (Pierce, Rockford, IL, USA). To minimize inter-run variability, each gel contained four patients and four controls in an alternating order.

NanoLC-MS/MS analysis

Before NanoLC-MS/MS analysis, separated proteins were in-gel digested as previously described.²¹ Peptides were separated by an Ultimate 3000 nanoLC system (Dionex LC-Packings, Amsterdam, The Netherlands) equipped with a 20 cm x 75 μ m ID fused silica column custom packed with 3 μ m 120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, Ammerbuch-Entringen, Germany). After injection, peptides were trapped at 6 μ L/min on a 10 mm x 100 μ m ID 5 μ m 120 Å ReproSil Pur C18 aqua at 2% buffer B (buffer A: 0.05% FC in MilliQ; buffer B: 80% ACN + 0.05% FC in MilliQ). Peptides were separated at 300 nL/min in a 10-40% buffer B gradient in 60 minutes. Eluting peptides were ionized at a potential of +2 kV and injected in a QExactive mass spectrometer (Thermo Fisher, Bremen, Germany). Intact masses were measured at resolution 70,000 (at m/z 200) in the Orbitrap using an AGC target value of 3×10^6 charges. The top 10 peptide signals (charge-states 2⁺ and higher) were submitted to MS/MS in the higher-energy collision cell (4 amu isolation width, 25% normalized collision energy). MS/MS spectra were acquired at resolution 17,500 (at m/z 200) in the Orbitrap using an AGC target value of 2×10^5 charges and an underfill ratio of 0.1%. Dynamic exclusion was applied with a repeat count of 1 and an exclusion time of 30 seconds.

Protein identification and quantification

MS/MS spectra were searched against the Swissprot human 2018 reference proteome using MaxQuant 1.6.0.16.²² Enzyme specificity was set to trypsin and up to two missed cleavages were allowed. Cysteine carboxamidomethylation was set as fixed modification and methionine oxidation and N-terminal acetylation as variable modifications. Peptide precursor ions and fragment ions were searched with maximum mass deviation of 4.5 ppm and 20 ppm, respectively. All identifications were filtered at a false discovery rate (FDR) of 1% using the decoy database strategy. Protein abundance was quantified

by MS-signal intensity of the area under the chromatographic peak of the peptide precursor ion.

Statistical analysis

To identify differentially expressed proteins among the DLB and control groups raw intensities were processed using the label-free quantification (LFQ) algorithm in MaxQuant and MaxLFQ intensities were obtained.²³ Missing values were imputed from a normal distribution centered at the minimal intensity and a variance equal to the average variance across all proteins. Hierarchical clustering was performed on log10 normalized expression using the Euclidean distance and complete linkage for both sample clustering and protein clustering. Heatmaps were generated to visualize the normalized to zero mean unit variance (z-scores) for individual proteins. Differential expression analysis was performed with the limma package available from the Bioconductor package.²⁴

Proteomic analysis in CSF samples of AD, FTD and PD patients

We obtained proteomic data from CSF samples from AD and FTD patients that were generated in previous, published²⁵ and yet unpublished studies from our group. The proteomic analyses were performed using a similar workflow as the proteomic workflow described above. As part of a parallel study (PRODIA Memorabel Project), the generated raw proteomic data of AD, FTD and DLB patients included in cohort 1 and cohort 2 were reanalyzed against the same reference database (Swissprot human 2018 reference proteome using MaxQuant 1.6.0.16). In addition, we obtained CSF proteomic data provided by the BioFind database. CSF samples from PD patients were analyzed using state-of-the-art DEEP SEQ mass spectrometry technology.²⁶ The PD data were searched against a human protein database (uniprot.org) with Mascot.

Orthogonal methods for validation of candidate biomarkers

For Neurosecretory protein VGF (VGF) and Neuronal pentraxin 2 (NPTX2), we performed additional validation experiments using orthogonal techniques (i.e., ELISA and SRM) in cohort 3B. For VGF, CSF levels of the VGF₃₇₃₋₄₁₇ peptide were measured by quantitative competitive ELISA²⁷⁻²⁹ and by SRM (see detailed description below). CSF levels of NPTX2 were detected using a quantitative sandwich ELISA, as previously described.³⁰

ELISA analysis of VGF

The human VGF₃₇₃₋₄₁₇ ELISA was carried out as described,^{27, 28} on the basis of the corresponding rat VGF₃₇₅₋₄₂₀ assay.²⁹ A synthetic peptide corresponding to human VGF₃₇₃₋₃₈₂ (conjugated with keyhole limpet haemocyanin via an additional C-terminal Cysteine),

was used for rabbit immunizations. Briefly, plates were coated with the corresponding synthetic peptide in carbonate/bicarbonate buffer (pH 9.6), blocked in PBS-Tween 20 containing normal donkey serum (90 mL/L), aprotinin (20 nmol/L) and EDTA (1 g/L), and incubated with a mixture of primary antibody (in the same medium) and serial dilutions of either standard peptide, or samples. For the standard curve, a range of concentrations (50 nmol/L to 50 fmol/L) of either VGF₃₇₃₋₃₈₂ or VGF₃₇₃₋₄₁₇ (GGEE-45) synthetic peptide was used. The latter was identified as a natural peptide in human CSF,³¹ hence was used as “full length” reference. After primary incubation, plates were washed, treated with biotinylated secondary antibodies (Jackson, West Grove, PA, USA), streptavidin-peroxidase conjugate (Biospa, Milan, Italy), and tetramethylbenzidine (X-tra Kem-En-Tec, Taastrup, Denmark). The reaction was stopped with HCl (1 mol/L), and optical density was measured at 450 nm using a multilabel plate reader (Chameleon: Hidex, Turku, Finland). Assay characterization showed: 50% inhibition of signal was obtained at 10 pmol/L standard peptide; recovery of peptide added to human CSF was >80%; intra- and inter-assay coefficients of variation (CV%) were 4% and 10%, respectively. Serial sample dilutions showed a profile parallel to the standard curve (deviation: <10%). When data were tested versus duration of sample storage (at -80°C, 1 to >10 years), no correlation was revealed. To gain some insight as to the specificity of the assay for N-terminally cleaved peptides, vs. the same sequence within N-terminally extended forms (possibly including the VGF precursor), a synthetic peptide containing an additional N-terminal Arg residue was tested in the assay (corresponding to Arg₃₇₂ in the di-basic site: human VGF Arg₃₇₁-Arg₃₇₂ immediately preceding the natural peptide VGF₃₇₃₋₄₁₇ and implicated in its N-terminal cleavage). The data showed a <0.5% cross-reactivity for this peptide, hence indicating a high specificity of the assay for the N-terminally cleaved peptide.

SRM analysis of VGF

For SRM analysis of VGF in CSF samples, 200µL of CSF was spiked with TEAB buffer and a quantitative protein epitope signature tag (QPrEST, kindly provided by Atlas Antibodies AB, #QPrEST20926) of VGF as internal standard. Samples were reduced and alkylated with 1mM TCEP and 1mM CAA at 95°C for 10min. Proteins were digested for 16h at 37°C by adding 1.2µg trypsin/LysC (Promega). Digestion was stopped by addition of 800µL 1.25% TFA and peptides were transferred to strong cation exchange STAGE-Tips³² by centrifugation. Peptides were washed with 0.2% TFA followed by 75mM ammonium acetate/20% acetonitrile/0.5% formic acid and eluted with 125mM ammonium acetate/20% acetonitrile/0.5% formic acid. After vacuum drying, peptides were dissolved in 30µL 6% acetonitrile/0.1% TFA and analyzed by LC-SRM. Analysis of VGF was performed with a QTRAP6500 mass spectrometer (AB Sciex), Eksigent MicroLC200 and Agilent 1260 HPLC pump. Peptides were loaded on a C18 PepMap100, 5µm, 0.3x5

mm trap column (Thermo Fisher Scientific). Separation was performed on an Eksigent HALO Fused-core C18, 2.7 μ m, 0.5x100 mm column at 40 °C with mobile phase A: 4% DMSO/0.1% formic acid, and mobile phase B: 4% DMSO/96% acetonitrile/0.1% formic acid and a linear gradient from 1%-30%B within 9.85min. The following transitions of the proteotypic VGF peptide AQEEAEAEER (aa586-595) were measured: 581.3-962.4 (y8), 581.3-833.4 (y7), 581.3-704.3 (y6) (light peptide); 586.3-972.4 (y8), 586.3-843.4 (y7), 586.3-714.3 (y6) (heavy peptide). For relative quantification, the light-to-heavy (L/H) peptide ratio (mean of the three transitions) was calculated using Skyline v4.2. CSF QC samples were included in each run. Intra-assay CVs were 5.1-7.9%.

Statistical analysis

All statistical analyses were performed in R v.3.5.1 'Feather Spray'. Demographics were compared using Student's t-test, Wilcoxon signed-rank test or Fisher's Exact Test. Correlations between identified CSF biomarkers and age, sex and MMSE were assessed with Spearman partial correlation, adjusted for cohort. For the validation of the identified candidate biomarker levels in related neurodegenerative diseases (cohort 3A), all protein levels were first normalized according to the mean and standard deviation values of their corresponding control group. The obtained z-scores were compared using general linear models corrected for age. In addition, we performed random forest analyses³³ with the R package randomForest using automated parameter optimization with the caret package to identify a subset of candidate markers that best distinguished DLB from all other groups. We used Monte Carlo sampling with replacement to sample test groups to generate a random forest classifier with the minimum number of predictors, and used the left out data to test the resulting classifier. This procedure was repeated for 1000 iterations. Diagnostic groups differed in sample size, and to avoid class imbalance effects on classifier performance, we down-sampled the larger group to the same size as the smaller group for training. Classification performance on the test data was determined with accuracy, sensitivity and specificity using the R package "caret". In order to visualize separation in diagnoses for the combined top selected proteins, we performed k-means clustering on these proteins, including also age. Optimal number of clusters was determined on the within cluster sums of squares, based on the point after which only minimal additional variance was explained. Cluster solution was plotted against the first two dimensions. Finally, general linear models were performed to compare CSF levels of VGF and NPTX2 between DLB patients and controls in cohort 3B. A FDR-value <0.05 was considered statistically significant.

RESULTS

Patient characteristics

Table 1 displays the demographics and CSF characteristics of DLB patients and controls included in cohort 1, 2 & 3B. The diagnostic groups had similar age and sex distributions. DLB patients had lower MMSE cores compared to controls. Per inclusion criteria, all DLB patients in the cohort 1 and all controls had normal AD biomarker levels in CSF, whereas almost half of the DLB patients in cohort 2 & 3B had a CSF AD profile.

Phase 1: CSF biomarker discovery

In total, 1995 proteins were identified in the discovery cohort (cohort 1). A total of 69 unique proteins showed significantly different abundances ($p < 0.05$). Forty-six proteins were downregulated and 23 proteins were upregulated in DLB (Supplementary Table 1). Figure 2A shows the heatmap and cluster analysis of differentially expressed proteins. Hierarchical cluster analysis including the differentially expressed proteins revealed almost complete separate clustering of DLB patients and controls (87.5% were clustered correctly). The dendrogram illustrates the two distinct clusters: 15 DLB patients were assigned to cluster 1. Interestingly, the 5 DLB patients in cluster 2 clustered together in a subgroup (cluster 2A), while all 20 controls clustered together in subgroup 2B. The level of significance and the magnitude of changes of the quantitative data are visualized in a volcano plot (Figure 2B).

Table 1 | Demographics and CSF characteristics of DLB patients and controls

	Cohort 1 (n=40)		Cohort 2 (n=30)		Cohort 3B (n=76)#	
	DLB	Controls	DLB	Controls	DLB	Controls
N	20	20	17	13	48	28
Demographics						
Age	65.3 ± 5.8	65.1 ± 5.4	66.9 ± 7.5	65.6 ± 8.5	67.8 ± 6.3*	64.1 ± 5.8
Sex (% Male)	17 (85%)	17 (85%)	13 (76%)	9 (69%)	42 (88%)	24 (86%)
Symptom duration (years)	3 [2-4]	N/A	2 [2-4]	N/A	2 [1-4]	N/A
MMSE	23 [21-26]***	28 [27-29]	26 [21-28]*	29 [28-30]	23 [21-26]***	28 [27-30]
APOE ε4 carrier	9 (45%)	8 (40%)	10 (71%)**	2 (17%)	25 (55%)	10 (38%)
CSF AD biomarkers						
Aβ42 (pg/ml)	846 [637-1011]	820 [691-1039]	611 [478-942]*	959 [932-1054]	660 [536-871]**	856 [691-1027]
Abnormal	0 (0%)	0 (0%)	8 (47%)	0 (0%)	13 (27%)	0 (0%)
t-tau, (pg/ml)	238 [200-286]	209 [167-266]	317 [268-599]**	226 [194-253]	299 [224-370]***	190 [156-257]
Abnormal	0 (0%)	0 (0%)	8 (47%)	0 (0%)	11 (23%)	0 (0%)
p-tau, (pg/ml)	37 [29-47]	42 [31-47]	46 [41-71]	41 [37-49]	47 [34-61]*	38 [28-46]
Abnormal	0 (0%)	0 (0%)	7 (41%)	0 (0%)	18 (37%)	0 (0%)

Data are presented as mean ± SD for normally distributed continuous variables, as median [first quartile - third quartile] for non-normally distributed continuous variables or as n (%) for categorical variables. CSF cutoff values were set on Aβ42 < 550 pg/ml, t-tau > 375 pg/ml, p-tau > 52 pg/ml¹⁷. Differences between DLB patients and controls were assessed with Student's t-test, Wilcoxon signed-rank test or Fisher's Exact Test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. #NPTX2 ELISA: n=76 (DLB: n=48, Controls: n=28); VGF ELISA: n=66 (DLB: n=44, Controls: n=22); VGF SRM: n=65 (DLB: n=44, Controls: n=21) Abbreviations: Aβ42, Amyloid-β 1-42; AD, Alzheimer's disease; APOE, Apolipoprotein E; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; MMSE, Mini mental State examination (score range 0-30); N/A, Not applicable; p-tau, Tau phosphorylated at threonine 181; t-tau, total Tau protein.


Phase 2: Validation using identical proteomic workflow in an independent cohort

Next, we performed a replication in a completely independent second cohort (17 DLB patients, 13 controls) to validate the results (cohort 2, Table 1). Here, 1967 proteins were identified, of which 93 proteins were differentially expressed ($p < 0.05$, Supplementary Table 2). Overlap analysis between the differentially expressed proteins ($p < 0.05$) showed six proteins with same direction and magnitude of change in both cohorts, i.e. Neurosecretory protein (VGF), Secretogranin-2 (SCG2), Neuronal pentraxin-2 (NPTX2), Neuronal pentraxin receptor (NPTXR), Proenkephalin-B (PDYN) and ProSAAS (PCSK1N) (Table 2).

Table 2 | Overlapping differentially expressed proteins between cohort 1 and 2

Uniprot ID	Gene name	Protein name	Fold change in discovery cohort	Fold change in validation cohort	CSF Peer literature (see Suppl. Table 3 for references)
O15240	VGF	Neurosecretory protein VGF	-1.78	-1.41	↓ in AD, FTD and ALS ↑ in schizophrenia
P13521	SCG2	Secretogranin-2	-1.36	-1.30	↓ in MS ↓ in AD
P47972	NPTX2	Neuronal pentraxin-2	-1.55	-1.50	↓ in AD
O95502	NPTXR	Neuronal Pentraxin Receptor	-1.31	-1.32	↓ in AD
P01213	PDYN	Proenkephalin-B	-4.33	-8.78	↓ in AD
Q9UHG2	PCSK1N	ProSAAS	-1.22	-1.21	↓ in AD ↓ in FTD


Table lists the six CSF biomarker candidates for DLB. A positive fold change indicates that the protein is upregulated in the DLB group in contrast to the control group. A negative fold change indicates the protein is downregulated in the DLB group compared to the control group. Abbreviations: AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; DLB, Dementia with Lewy bodies; FTD, Frontotemporal dementia; MS, Multiple sclerosis; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor, PCSK1N, ProSAAS; PDYN, Proenkephalin-B; SCG2, Scretogranin-2; VGF, Neurosecretory protein VGF.

Figure 2 | Results of discovery proteomics

(A) Heatmap and cluster analysis of differentially expressed proteins ($n=69$) in cohort 1. The heatmap shows distinct patterns of up- and downregulated proteins in the clinical groups. The branching pattern of the dendrogram shows almost complete separation of patients with DLB from cognitively normal controls (35/40 (87.5%) were clustered correctly). 15 DLB patients were assigned to cluster 1 (red) and five DLB patients and 20 controls were assigned to cluster 2. The five DLB patients in cluster 2 clustered together in a small subgroup (cluster 2A, purple) and the controls clustered together in another subgroup (cluster 2B, blue). (B) Volcano plot representing the top biomarker candidates discriminating DLB from controls. The horizontal axis indicates \log_2 fold change. The vertical axis indicates $-10 \log p$ -values. Each point represents a protein. Points at the far right- and left-hand sides of the plot have the largest fold changes, while those along the top of the plot are the most statistically significant. The non-axial red dotted vertical lines denote fold change thresholds of 1.2. The non-axial red dotted horizontal line denotes p -value threshold of 0.05. Proteins in red have a fold change > 1.2 and p -value < 0.05 . The top-10 biomarker candidates are highlighted in the plot.

Figure 3 shows the individual levels of these six candidate biomarkers in both cohort 1 and 2. CSF levels of all these proteins were lower in DLB patients compared to controls (all $p < 0.05$). Next, we explored whether these six candidate biomarkers were associated with age, sex and cognitive impairment. Partial spearman correlation analysis adjusted for cohort revealed that lower CSF levels of all proteins, except PCSK1N, were associated with lower MMSE scores at time of lumbar puncture ($0.37 < r < 0.56$, all $p < 0.01$; Figure 4), whereas no associations were found with age and sex (data not shown).

Figure 3 | Box and Whisker plots of candidate CSF biomarkers for DLB




(A) Log₁₀ LFQ intensity of VGF in cohort 1, (B) VGF in cohort 2, (C)(D) SCG, (E)(F) NPTX2, (G)(H) NPTXR, (I) (J) PDYN, (K)(L) PCSK1N. The line through the middle of the boxes corresponds to the median and the lower and the upper lines to the 25th and 75th percentile, respectively. The whiskers extend from the 5th percentile on the bottom to the 95th percentile on top. Differences between DLB patients and controls were assessed limma package available from the Bioconductor package, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Abbreviations: DLB, dementia with Lewy bodies; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor, PCSK1N, ProSAAS; PDYN, Proenkephalin-B; SCG2, Secretogranin-2; VGF, Neurosecretory protein.

Phase 3A: Validation of candidate CSF biomarkers in related neurodegenerative diseases

Next, we investigated the candidate biomarker values in related neurodegenerative diseases, including AD, PD and FTD (Figure 5A). CSF levels of the candidate biomarkers, except PCSK1N, were in general lower in all neurodegenerative patient groups compared to the control group. Protein levels were consistently lowest in DLB patients. Specifically, CSF NPTX2 levels were lower in DLB compared to both AD and PD ($p < 0.05$). CSF NPTXR levels were lower in DLB than in PD ($p < 0.05$). CSF levels of PCSK1N were lower in DLB compared to both PD and FTD ($p < 0.05$). CSF levels of PDYN, SCG2 and VGF were lower in DLB compared to all related neurodegenerative diseases studied ($p < 0.05$). CSF levels of all proteins were comparable between the other neurodegenerative disease, i.e. AD, PD and FTD, except VGF for which levels were lower in AD compared to FTD ($p < 0.05$).

Figure 4 | Associations between the six CSF candidate biomarkers for DLB and MMSE



Scatter plots of MMSE and CSF levels of (A) VGF (B) SCG2, (C) NPTX2, (D) NPTXR, (E) PDYN, (F) PCSK1N across DLB (red) and control groups (blue). Individual subject cohort 1 are depicted as squares and individual subjects from cohort 2 are depicted as triangles. Associations were assessed using Spearman partial correlation adjusted for cohort. To correct for multiple comparisons, p -values were corrected using a false discovery rate (FDR) correction. Abbreviations: DLB, dementia with Lewy bodies; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor, PCSK1N, ProSAAS; PDYN, Proenkephalin-B; SCG2, Scretogranin-2; VGF, Neurosecretory protein VGF.

The identified markers still showed considerable overlap between groups, suggesting limited ability for diagnostic purposes as single markers. Therefore, we performed random forest analyses to study whether a combination of biomarkers improved discrimination between DLB and all non-DLB individuals. VGF, SCG2 and PDYN best differentiated between DLB and all non-DLB, with accuracy of 0.82, specificity of 0.83 and sensitivity of 0.69 (Table 3). To visualize separation in clinical diagnosis for the combined top selected proteins, we performed k-means clustering on these proteins, including also age (Supplementary Figure 1). Subsequently, we performed pairwise comparisons between DLB versus all other clinical groups using this model. Table 3 shows a summary of the pairwise diagnostic classification results. The panel discriminated DLB other clinical groups with accuracies ranging from 76% to 89%. The specificity of all pairwise comparisons was high (0.80-1.00) while sensitivity was moderate (0.72-0.85).


Table 3 | Diagnostic performance of a biomarker panel for DLB versus other clinical groups

DLB versus	Accuracy (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
All non-DLB	0.82 (0.75-0.89)	0.69 (0.41-0.98)	0.83 (0.74-0.90)
Controls	0.84 (0.77-0.89)	0.77 (0.46-1.00)	0.85 (0.76-0.93)
PD	0.79 (0.69-0.87)	0.72 (0.43-0.93)	0.80 (0.66-0.90)
AD	0.89 (0.85-0.99)	0.85 (0.79-0.99)	1.00 (1.00-1.00)
FTD	0.76 (0.61-0.92)	0.73 (0.55-0.95)	0.86 (0.59-1.00)

All protein levels were Z transformed according to the mean and standard deviation in controls. Abbreviations: AD, Alzheimer's disease; DLB, dementia with Lewy bodies; FTD, Frontotemporal dementia; PD, Parkinson's disease.

Phase 3B: Validation of candidate CSF biomarkers by ELISA and SRM

Finally, VGF and NPTX2 were selected for validation in cohort 3 based on the availability of orthogonal analytical methods (ELISA and SRM). As shown in Figure 5B, decreased levels of CSF VGF (VGF₃₇₃₋₄₁₇ in ELISA) and NPTX2 were confirmed using these alternative analytical methods ($p < 0.01$ and $p < 0.001$, respectively).

Figure 5 | Validation of candidate biomarkers

(A) Differences in levels of candidate biomarkers between DLB and related neurodegenerative diseases. All protein levels were Z transformed according to the mean and standard deviation in controls, dotted line represents average protein levels for the control group. For PDYN, 4 outliers (z -score >20) were illustrated in a box. Please note that the low variation in PDYN levels in AD patients is caused by a lack of a measurable concentration. Differences were assessed with GLM corrected for age and a FDR correction was applied. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. (B) Validation of VGF and NPTX2 using orthogonal analytical methods. Levels of VGF₃₇₃₋₄₁₇ (pmol/ml) were determined by ELISA, levels of VGF [LH/ratio] were determined with SRM and levels of NPTX2 (pg/ml) were determined with ELISA in CSF samples from DLB patients ($n=48$) and controls ($n=28$). The line through the middle of the boxes corresponds to the median and the lower and the upper lines to the 25th and 75th percentile, respectively. The whiskers extend from the 5th percentile on the bottom to the 95th percentile on top. Differences between DLB patients and controls were assessed with GLM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Abbreviations: AD, Alzheimer's disease; DLB, dementia with Lewy bodies; ELISA, enzyme-linked immunosorbent assays; FTD, frontotemporal dementia; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor; PCSK1N, ProSAAS; PD, Parkinson's disease; PDYN, Proenkephalin-B; SCG2, Secretogranin-2; SRM, selected reaction monitoring; VGF, Neurosecretory protein VGF.

DISCUSSION

Using a state-of-the-art rigorous proteomic approach and validation in a completely independent cohort, we identified and positively validated six promising CSF biomarker candidates for DLB, namely VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N (proSAAS). All six biomarker candidates were downregulated in DLB and levels were consistently lowest in DLB patients compared to related neurodegenerative diseases studied, i.e. AD, PD and FTD. Additionally, we utilized machine learning to identify the biomarker panel best capable of classifying DLB patients. The combination of VGF, SCG2 and PDYN best differentiated between DLB and related neurodegenerative diseases with acceptable specificity and sensitivity. In a second validation step, we confirmed the decrease of CSF VGF (ELISA, SRM) and NPTX2 (ELISA) using orthogonal analytical techniques. Low CSF levels of all biomarker candidates, except PCSK1N, were associated with more pronounced cognitive decline. We will discuss these validated biomarker candidates below.

Three identified biomarker candidates (VGF, SCG2 and PCSK1N) are members of the chromogranin/secretogranin family and play a role in the regulated secretory pathway of peptides, hormones, neurotransmitters and growth factors. VGF topped the list of potential biomarker candidates. Biologically active peptides derived from VGF play an important role in diverse processes, for example, hormone, neurotrophin and neurotransmitter release, energy homeostasis and regulation of gastrointestinal function.^{34,35} Although VGF peptides have so far not been associated with DLB, previous proteomic studies observed changes in VGF peptides in the CSF of patients affected with several neurodegenerative and psychiatric disorders. In line with our findings in DLB, multiple VGF peptides were shown to be decreased in CSF from patients with AD, FTD (VGF₂₆₋₆₂) or amyotrophic lateral sclerosis (ALS) (VGF₃₉₈₋₄₁₁). In addition, VGF peptides were also reduced in brain tissue of patients with PD.³⁶ Conversely, CSF levels of VGF₂₃₋₆₂ were increased in schizophrenia patients (see Supplementary Table 3 for an overview of the literature). The second biomarker candidate SCG2 is involved in the packing or sorting of peptide hormones and neuropeptides into secretory vesicles, and plays a role in inflammatory responses and in the regulation of the blood pressure.³⁴ Consistent with our findings, reduced levels of CSF SCG2 in AD and multiple sclerosis (MS) have been reported (Supplementary Table 3). In view of the decrease of VGF and SCG2 in CSF of patients with different neurodegenerative disorders and their localization in synaptic vesicles, we propose that VGF and SCG2 are markers for synaptic degeneration. Third, PCSK1N, an inhibitor of prohormone convertase (PC) activity,³⁴ has also been proposed as a CSF biomarker candidate for several neurological disorders. For example, reduced

levels of CSF PCSK1N in AD and FTD have been reported (Supplementary Table 3). Moreover, several lines of evidence have implicated that PCSK1N blocks aggregation of A β 42 and α -synuclein,^{37,38} supporting a function of PCSK1N as a neuronal secretory chaperone in DLB.

NPTX2 and NPTXR are members of the neuronal pentraxin family.³⁹ The neuronal pentraxin family has not previously been related to DLB. However, NPTX2 and NPTXR were also reduced in AD (Supplementary Table 3). NPTX2 promotes formation of new excitatory synapses and regulation of AMPA-type receptors clustering at established synapses.⁴⁰ The altered levels of NPTX2 and NPTXR further substantiate the importance of synaptic dysfunction in the pathophysiology of DLB. In contrast to the results in AD and DLB, both the gene and tissue expression of NPTX2 were upregulated in PD.⁴¹ We showed that CSF NPTX2 levels in DLB were lower compared to both AD and PD patients. The reduction of NPTX2 that is correlated with cognitive decline implicates a pathophysiological mechanism – failure of the adaptive function of pyramidal neurons to modify excitatory drive of fast spiking parvalbumin (PV) interneurons- that could potentially be targeted for therapeutics.⁴²

The sixth biomarker candidate that we identified and validated was PDYN. The large decrease (fold change of >4) suggest that PDYN is an on/off marker (i.e. subjects either have low PDYN levels or have high PDYN levels). More DLB patients than controls have very low PDYN levels resulting in an average decreased expression in DLB (Figure 3). PDYN is a precursor protein that is processed by PC1, PC2 and carboxypeptidase E to form different opioid neuropeptides (collectively referred to as dynorphins).⁴³ The effects of dynorphins are mediated through two kinds of receptors: (1) k-opioid receptor (KOP) and (2) NMDA or AMPA receptors. Dysregulation of the dynorphin/KOP system may contribute to behavioral abnormalities that are commonly shared by psychiatric disorders (i.e. decreased motivation and negative affect),⁴⁴ while non-opioid effects of dynorphins on NMDA or AMPA receptors could result in apoptosis and neurodegeneration.⁴⁵ Consistent with the decreased levels of PDYN in DLB in our study, reduced dynorphin levels have also been observed in CSF from AD patients (Supplementary Table 3) and in the amygdala of patients diagnosed with major depression and bipolar disorder.⁴⁶ Interestingly, a substantial loss of hypothalamic cells producing hypocretin, PDYN and NPTX2 has been found in patients with narcolepsy.⁴⁷⁴⁸ Patients with narcolepsy suffer from symptoms that are also present in DLB, such as excessive daytime sleepiness, hypnagogic hallucinations and RBD.⁴⁹ The overlap in symptoms might suggest a common etiology between DLB and narcolepsy and

indicates that PDYN and NPTX2 reduction may be important biological substrates underlying sleep-related symptoms in DLB.

The identification of these candidate biomarkers highlights the importance of synaptic dysfunction in DLB. This is in line with previous research indicating that this biological process is a central feature in DLB pathogenesis.⁵⁰⁻⁵² However, the mechanisms leading to synaptic dysfunction in DLB remain elusive. Growing evidence indicates that accumulation of α -synuclein at presynaptic sides may contribute towards explaining synaptic dysfunction in DLB.^{50, 51, 53, 54} A prevailing hypothesis is that excessive α -synuclein leads to deficits in vesicular transport/trafficking resulting in functional impairment of neurotransmitter release at the synapse^{50, 51, 53, 54} Synaptic dysfunction is thought to precede neuronal degeneration in DLB, and may correlate more directly with cognitive decline than pathological hallmarks such as Lewy bodies.⁵⁵ Indeed, most of the identified biomarker candidates were associated with cognitive decline in DLB. Our results provide support to the link between cognitive performance and synaptic protein loss in DLB.

Loss of synapses and a decrease in synaptic proteins are constant features of neurodegenerative diseases. This is also supported by similar synaptic protein changes in post-mortem brain tissue revealed by proteomic analysis from patients with AD, PD dementia and DLB.⁵⁵ The identified candidate biomarkers may therefore not be selectively reduced in DLB. Although synaptic dysfunction and loss is evident in neurodegenerative diseases, our findings tentatively suggest that synaptic dysfunction appears to be more pronounced in DLB than in related neurodegenerative diseases, i.e. AD, PD and FTD, or may reflect differing synaptic deficits among neurodegenerative diseases. Of note, the downregulation of the identified proteins in DLB is unlikely to be caused by concomitant AD pathology, since all DLB patients in cohort 1 and most DLB patients in cohort 2B and 3B had normal CSF AD biomarker levels. Most candidate biomarkers, however, showed considerable overlap between diagnostic groups, suggesting limited ability for diagnostic purposes as single markers. Random forest analyses suggested that VGF, SCG2 and PDN combined could best differentiate between DLB and all non-DLB individuals with a high specificity and moderate sensitivity. Despite the somewhat lower sensitivity, a vital characteristic for a biomarker (panel) is its specificity, i.e. the ability of a biomarker (panel) to correctly identify all people who not have the condition of interest, in determining disease state. Clinical symptoms are quite sensitive, but lack specificity in terms of distinguishing DLB from other types of neurodegenerative diseases, therefore, the identified biomarker panel could importantly add to the clinical work-up of DLB. Possibly, other combinations of proteins measured with modern discovery studies may further aid in differentiating between

diagnoses, and future research in larger sample sizes should further investigate this question.

Among the strengths of the current study are the use of a rigorous in-depth proteomic approach, replication in an independent cohort, validation of the biomarker candidates in related neurodegenerative diseases, including AD, PD and FTD, validation of a subset of biomarker candidates using orthogonal techniques, and the strict inclusion criteria for patients and controls. For example, an abnormal DAT-SPECT scan and normal AD biomarker levels were obligatory for all DLB patients in the discovery cohort. On the other hand, DLB patients in the validation cohorts were more heterogeneous, i.e. DLB patients were more representative of DLB patients in daily memory clinic practice, as they were not selected based on their CSF AD biomarker values and almost half of the DLB patients had a CSF profile compatible with AD (in line with previous literature).⁵⁶ The use of this study design increases the generalizability of our findings. These strengths make the current study the most comprehensive proteomic analysis in DLB so far. Our study has nonetheless also limitations. A potentially important drawback is that the proteomic pipeline is biased towards the identification of more abundant proteins. This is particularly a problem in mass spectrometry-based proteomic analysis of CSF, since most proteins secreted from the brain into the CSF (e.g. cytokines and neuropeptides) have low concentrations (~ 150 mg/mL). For example, several known key pathological determinants of DLB, including α -synuclein and A β 42, were not detected, since their concentration are below the typical limit of detection of mass spectrometry methods. In addition, these proteins can be highly post-translationally modified, which further compromises mass spectrometry-based identification by default search strategies. Hence, the possibility cannot be excluded that we may have missed some potentially interesting proteins. Furthermore, proteomic data of the PD patients were obtained from a different mass spectrometry platform than the proteomic data of the AD, DLB and FTD patients, which could have introduced some noise. However, normalization of the biomarker candidate values relative to the corresponding control group could restrict the methodological differences. Additionally, the random forest classifier was generated and tested in the same cohort which may lead to over-optimistic classification results. Although we have used bootstrapping to reduce such over-fitting, larger cohorts are needed to validated these findings as well as to examine the added diagnostic value of the (combination of) candidate proteomic markers in relation to the established AD biomarkers and α -synuclein. Such a study would be of tremendous value to the field by optimizing biomarker panel for fit-for-use purposes, as well as to evaluate the role of synaptic dysfunction in the pathogenesis of neurodegeneration.

In conclusion, we identified and positively validated six novel proteins (VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N) as promising biomarkers for DLB. Our results might suggest that these candidate biomarkers, particularly when used as a panel, show promise to improve diagnostic accuracy for DLB, which should be explored in future prospective validation studies. Moreover, the validation using orthogonal techniques (i.e. high-throughput immunoassays or SRM) of a subset of the candidate biomarkers revealed by the proteomics approach supports the robustness of our findings. Therefore, future studies should include a replication in independent cohorts including patients with different neurodegenerative diseases (at least: DLB, AD, PD), and testing our panel of synaptic biomarkers, in combination with the AD biomarkers, using such higher throughput techniques (e.g. SRM). Identification of these candidate biomarkers also strengthens the importance of synaptic dysfunction in the pathophysiology of DLB, which warrant further research as potential therapeutic target. On the applicative and clinical side, the identification of novel CSF biomarkers for DLB, can be expected to enhance clinical diagnostic accuracy, especially early in the disease course, and might thereby accelerate the development of new disease-modifying and neuroprotective agents.

Acknowledgements

Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. This study is further funded by the Scientific Excellence Program of Amsterdam Neuroscience and the Memorabel grant programme of the Nederlands Organisation of Health Research and Development (ZonMW grants: 733050509, 733050102, 733050206 and 733050824). The study was additionally supported by grants from the German Federal Ministry of Education and Research (project FTLDc 01GI1007A); the EU Joint Programme–Neurodegenerative Diseases networks PreFrontAls (01ED1512), the foundation of the state of Baden-Wuerttemberg, the German science foundation (DFG; SFB 1237), and the Regione Sardegna, Italy “Fundamental and Basic research Grant” (2012-CRP-60834). VUmc-CCA and ZonMW (Middelgroot grant 91116017) are acknowledged for support of proteomic infrastructure. Data of PD patients used in the preparation of this article were obtained from the Fox Investigation for New Discovery of Biomarkers (“BioFIND”) database (<http://biofind.loni.usc.edu/>). For up-to-date information on the study, visit www.michaeljfox.org/biofind. BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) with support from the National Institute for Neurological Disorders and Stroke (NINDS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *Lancet*. 2015 Oct 24;386(10004):1683-97.
2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017 Jul 4;89(1):88-100.
3. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. *The Lancet Neurology*. 2011 Nov;10(11):1015-25.
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol*. 2010 Mar;6(3):131-44.
5. Teunissen CE, Otto M, Engelborghs S, et al. White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. *Alzheimers Res Ther*. 2018 Mar 15;10(1):30.
6. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2018 Apr;14(4):535-62.
7. van Steenoven I, Majbour NK, Vaikath NN, et al. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. *Movement disorders : official journal of the Movement Disorder Society*. 2018 Nov 15.
8. Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimers Res Ther*. 2014;6(3):25.
9. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. *Exp Neurol*. 2008 Oct;213(2):315-25.
10. Aebersold R, Mann M. Mass spectrometry-based proteomics. *Nature*. 2003 Mar 13;422(6928):198-207.
11. Carlyle BC, Trombetta BA, Arnold SE. Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. *Proteomes*. 2018 Aug 31;6(3).
12. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. *J Alzheimers Dis*. 2006 Aug;9(3):293-348.
13. Dieks JK, Gawinecka J, Asif AR, et al. Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies. *J Alzheimers Dis*. 2013;34(2):387-97.
14. Heywood WE, Galimberti D, Bliss E, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Mol Neurodegener*. 2015 Dec 1;10:64.
15. van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. *J Alzheimers Dis*. 2014;41(1):313-27.
16. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology*. 2005 Dec 27;65(12):1863-72.

17. Mulder C, Verwey NA, van der Flier WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. *Clin Chem*. 2010 Feb;56(2):248-53.
18. Kang UJ, Goldman JG, Alcalay RN, et al. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. *Movement disorders : official journal of the Movement Disorder Society*. 2016 Jun;31(6):924-32.
19. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. *Clinical biochemistry*. 2014 Mar;47(4-5):288-92.
20. Fratantoni SA, Piersma SR, Jimenez CR. Comparison of the performance of two affinity depletion spin filters for quantitative proteomics of CSF: Evaluation of sensitivity and reproducibility of CSF analysis using GeLC-MS/MS and spectral counting. *Proteomics Clin Appl*. 2010 Jul;4(6-7):613-7.
21. Piersma SR, Warmoes MO, de Wit M, de Reus I, Knol JC, Jimenez CR. Whole gel processing procedure for GeLC-MS/MS based proteomics. *Proteome Sci*. 2013 Apr 23;11(1):17.
22. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol*. 2008 Dec;26(12):1367-72.
23. Cox J, Hein MY, Lubner CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics*. 2014 Sep;13(9):2513-26.
24. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004;3:Article3.
25. Teunissen CE, Elias N, Koel-Simmelink MJ, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. *Alzheimers Dement (Amst)*. 2016;2:86-94.
26. Zhou F, Lu Y, Ficarro SB, et al. Genome-scale proteome quantification by DEEP SEQ mass spectrometry. *Nat Commun*. 2013;4:2171.
27. D'Amato F, Cocco C, Noli B, Cabras T, Messana I, Ferri GL. VGF peptides upon osmotic stimuli: changes in neuroendocrine regulatory peptides 1 and 2 in the hypothalamic-pituitary-axis and plasma. *J Chem Neuroanat*. 2012 Jul;44(2):57-65.
28. Noli B, Brancia C, D'Amato F, Ferri GL, Cocco C. VGF changes during the estrous cycle: a novel endocrine role for TLQP peptides? *PLoS One*. 2014;9(10):e108456.
29. Noli B, Sanna F, Brancia C, et al. Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment. *Front Cell Neurosci*. 2017;11:158.
30. Xiao MF, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in Alzheimer's Disease. *Elife*. 2017 Mar 23;6.
31. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. *Proteomics*. 2003 Aug;3(8):1486-94.

32. Oeckl P, Metzger F, Nagl M, et al. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. *Mol Cell Proteomics*. 2016 Oct;15(10):3126-38.
33. Breiman L. Random forests. *Mach Learn*. 2001 Oct;45(1):5-32.
34. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. *Endocr Rev*. 2011 Dec;32(6):755-97.
35. Ferri GL, Noli B, Brancia C, D'Amato F, Cocco C. VGF: an inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers. *J Chem Neuroanat*. 2011 Dec;42(4):249-61.
36. Cocco C, D'Amato F, Noli B, et al. Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases. *J Anat*. 2010 Dec;217(6):683-93.
37. Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I. A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. *J Neurochem*. 2014 Feb;128(3):419-30.
38. Jarvela TS, Lam HA, Helwig M, et al. The neural chaperone proSAAS blocks alpha-synuclein fibrillation and neurotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*. 2016 Aug 9;113(32):E4708-15.
39. Xu D, Hopf C, Reddy R, et al. Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. *Neuron*. 2003 Jul 31;39(3):513-28.
40. O'Brien RJ, Xu D, Petralia RS, Steward O, Huganir RL, Worley P. Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp. *Neuron*. 1999 Jun;23(2):309-23.
41. Moran LB, Hickey L, Michael GJ, et al. Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. *Acta Neuropathol*. 2008 Apr;115(4):471-8.
42. Chang MC, Park JM, Pelkey KA, et al. Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. *Nat Neurosci*. 2010 Sep;13(9):1090-7.
43. Schwarzer C. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. *Pharmacol Ther*. 2009 Sep;123(3):353-70.
44. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. *Cell Mol Life Sci*. 2012 Mar;69(6):857-96.
45. Singh IN, Goody RJ, Goebel SM, et al. Dynorphin A (1-17) induces apoptosis in striatal neurons in vitro through alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor-mediated cytochrome c release and caspase-3 activation. *Neuroscience*. 2003;122(4):1013-23.
46. Hurd YL. Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. *Mol Psychiatry*. 2002;7(1):75-81.
47. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. *Neurology*. 2005 Oct 25;65(8):1184-8.
48. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. *Neuron*. 2000 Sep;27(3):469-74.

49. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest*. 2014 Nov;146(5):1387-94.
50. Colom-Cadena M, Pegueroles J, Herrmann AG, et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. *Brain : a journal of neurology*. 2017 Dec 1;140(12):3204-14.
51. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. *Acta Neuropathol*. 2010 Aug;120(2):131-43.
52. Calo L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M. Synaptic failure and alpha-synuclein. *Movement disorders : official journal of the Movement Disorder Society*. 2016 Feb;31(2):169-77.
53. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. *Brain : a journal of neurology*. 2014 May;137(Pt 5):1496-513.
54. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. *J Neurosci*. 2010 Jun 16;30(24):8083-95.
55. Berezcki E, Branca RM, Francis PT, et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. *Brain : a journal of neurology*. 2018 Feb 1;141(2):582-95.
56. van Steenoven I, Aarsland D, Weintraub D, et al. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. *J Alzheimers Dis*. 2016 Aug 18;54(1):287-95.

SUPPLEMENTAL DATA

Supplementary Table 1 | Differentially expressed proteins in cohort 1 based on mass spectrometry data analysis

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# Control samples
O15240	VEGF	Neurosecretory protein VGF	63.4	-1.777	1.62E-06	20	20
P13521	SCG2	Secretogranin-2	52.2	-1.357	8.96E-05	20	20
P47972	NPTX2	Neuronal pentraxin-2	43.9	-1.548	0.001	20	20
P05060	CHGB	Secretogranin-1	71.5	-1.265	0.001	20	20
CON__ENSEMBL:ENSBTAP00000006074			16.7	-1.618	0.001	0	1
P60842	EIF4A	Eukaryotic initiation factor 4A	20	-1.687	0.002	0	1
P19021;	PAM	Peptidyl-glycine alpha-amidating monoxygenase	56.2	-1.276	0.003	20	20
P01213	PDYN	Proenkephalin-B	42.9	-4.325	0.004	16	20
O95502	NPTXR	Neuronal pentraxin receptor	67	-1.305	0.005	20	20
P13760	HLA-DRB1	HLA class II histocompatibility antigen. DRB1-4 beta chain	44	10.047	0.005	14	5
P29279-	CTGF	Connective tissue growth factor	31.7	-1.229	0.006	20	20
P04440	HLA-DPB1	HLA class II histocompatibility antigen. DP beta 1 chain	29.1	-1.864	0.006	0	1
Q9UKZ9	PCOLCE2	Procollagen C-endopeptidase enhancer 2	6.5	1.795	0.007	1	0
Q15063	POSTN	Periostin	45.8	-4.435	0.008	10	17
P49747	COMP	Cartilage oligomeric matrix protein	53.8	-1.337	0.009	20	20
P55001	MFAP2	Microfibrillar-associated protein 2	12.4	-3.262	0.009	0	5
Q9BXJ3	C1QTNF4	Complement C1q tumor necrosis factor-related protein 4	57.8	-1.260	0.010	20	20
Q9BQ51	PDCD1LG2	Programmed cell death 1 ligand 2	12.6	-1.516	0.011	0	1
Q504Y2	PKDCC	Extracellular tyrosine-protein kinase PKDCC	17.4	1.959	0.011	2	0

Supplementary Table 1 | Differentially expressed proteins in cohort 1 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# Control samples
Q8WXD2	SCG3	Secretogranin-3	74.4	-1.204	0.013	20	20
Q5VSG8	MANEAL	Glycoprotein endo-alpha-1.2-mannosidase-like protein	51.4	-3.448	0.014	15	20
A6NL88	SHISA7	Protein shisa-7	7.4	-3.020	0.016	16	20
P02452	COL1A1	Collagen alpha-1(I) chain	26.1	-1.226	0.019	20	20
Q9ULH4	LRFN2	Leucine-rich repeat and fibronectin type-III domain-containing protein 2	16	-3.229	0.020	2	9
P30456	HLA-A	HLA class I histocompatibility antigen, A-43 alpha chain	54	1.453	0.020	1	0
Q68DQ2	CRYBG3	Very large A-kinase anchor protein	1.6	-1.557	0.021	0	1
Q16610	ECM1	Extracellular matrix protein 1	75.7	-1.158	0.022	20	20
P15509	CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor subunit alpha	36.9	3.247	0.022	19	13
P06703	S100A6	Protein S100-A6	16.7	2.985	0.022	4	0
Q6PCB0	VWA1	von Willebrand factor A domain-containing protein 1	41.1	-3.837	0.024	4	10
P04275	VWF	von Willebrand factor; von Willebrand antigen 2	48.2	-1.244	0.024	20	20
Q16849	PTPRN	Receptor-type tyrosine-protein phosphatase-like N	19.6	-2.408	0.024	18	20
Q6JBY9	RCS1	CapZ-interacting protein	9.4	1.352	0.025	0	1
Q4ZIN3	TMEM259	Membralin	3.4	-1.644	0.025	0	1

Supplementary Table 1 | Differentially expressed proteins in cohort 1 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# Control samples
P01031	C5	Complement C5	63.4	1.339	0.028	20	20
P05783	KRT18	Keratin, type I cytoskeletal 18	24.9	1.781	0.028	1	0
Q15768	EFNB3	Ephrin-B3	36.5	-1.211	0.028	20	20
P01859	IGHG2	Ig gamma-2 chain C region	36.2	-4.036	0.029	8	15
Q14DG7	TMEM132B	Transmembrane protein 132B	20.2	-3.279	0.029	13	18
P61812	TGFB2	Transforming growth factor beta-2	27.8	3.995	0.031	13	7
P08123	COL1A2	Collagen alpha-2(I) chain	25.5	-1.213	0.032	20	20
P16519	PCSK2	Neuroendocrine convertase 2	28.9	-1.833	0.032	19	20
Q9NY56	OBP2A	Odorant-binding protein 2a	35.9	3.300	0.033	4	0
Q06141	REG3A	Regenerating islet-derived protein 3-alpha	41.7	3.528	0.033	18	12
Q9Y2E5	MAN2B2	Epididymis-specific alpha-mannosidase	42.8	1.330	0.034	20	20
P07478	PRSS2	Trypsin-2	12.1	-7.192	0.034	13	18
Q9NY33	DPP3	Dipeptidyl peptidase 3	40.8	-2.795	0.035	14	18
Q63HQ2	EGFLAM	Pikachurin	38.4	3.074	0.035	20	17
P55087	AQP4	Aquaporin-4	15.3	2.274	0.035	4	0
Q15493	RGN	Regucalcin	53.2	-2.640	0.036	15	20
P52565	ARHGDI A	Rho GDP-dissociation inhibitor 1	22.5	-3.752	0.039	5	11
Q9UBX7	KLK11	Kallikrein-11	47.6	-1.244	0.039	20	20
Q9NTU7	CBLN4	Cerebellin-4	37.3	-1.377	0.040	20	20
Q9UHG2	PCSK1N	ProSAAS	68.5	-1.224	0.040	20	20
Q8IXA5	SPACA3	Sperm acrosome membrane-associated protein 3	7.5	1.471	0.042	1	0

Supplementary Table 1 | Differentially expressed proteins in cohort 1 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# Control samples
P62837	UBE2D2	Ubiquitin-conjugating enzyme E2 D2	14.3	5.977	0.042	11	5
Q9BUD6	SPON2	Spondin-2	36.3	-2.514	0.042	17	20
O14793	MSTN	Growth/differentiation factor 8	44.5	-1.205	0.044	20	20
Q9NS68	TNFRSF19	Tumor necrosis factor receptor superfamily member 19	8.9	2.217	0.044	4	1
Q9Y6C2	EMILIN1	EMILIN-1	20.4	2.575	0.045	17	12
Q4LDE5	SVEP1	Sushi. von Willebrand factor type A. EGF and pentraxin domain-containing protein 1	9.5	-2.750	0.045	8	14
Q6UY11	DLK2	Protein delta homolog 2	22.2	-2.187	0.045	17	20
Q30134	HLA-DRB1	HLA class II histocompatibility antigen. DRB1-8 beta chain	33.5	1.430	0.046	1	0
Q9UJMK7	MAN1B1	Endoplasmic reticulum mannosyl-oligosaccharide 1.2-alpha-mannosidase	33.8	-1.250	0.048	20	20
Q92932	PTPRN2	Receptor-type tyrosine-protein phosphatase N2	21.5	-1.230	0.048	20	20
O60486	PLXNC1	Plexin-C1	7.1	-1.369	0.048	0	1
P35613	BSG	Basigin	39.2	1.558	0.048	1	0
O94856	NFAS	Neurofascin	51.1	3.576	0.049	14	9
P02788	LTF	Lactotransferrin	66.5	5.211	0.049	18	13

List of 69 differentially expressed proteins in CSF from patients with DLB compared to CSF from cognitively normal controls ($p < 0.05$). Proteins in bold ($n = 44$) also fulfilled the predefined criteria for candidate biomarkers ($p < 0.05$, fold change > 1.2 , $> 20\%$ sequence coverage, detected in at least 50% of DLB patients or controls).

Supplementary Table 2 | Differentially expressed proteins in cohort 2 based on mass spectrometry data analysis

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# control samples
P05413	FABP3	Fatty acid-binding protein, heart	75.9	1.494	0.001	17	13
P09936	UCHL1	Ubiquitin carboxyl-terminal hydrolase isozyme L1	60.1	16.897	0.001	15	5
P13489	RNH1	Ribonuclease inhibitor	30.4	7.337	0.002	11	2
P63104	YWHAZ	14-3-3 protein zeta/delta	62.9	1.422	0.003	17	13
P62258	YWHAE	14-3-3 protein epsilon	79.2	1.309	0.003	17	13
P18669	PGAM1	Phosphoglycerate mutase 1	57.1	1.212	0.004	17	13
P52565	ARHGDI A	Rho GDP-dissociation inhibitor 1	22.5	4.740	0.005	17	8
P35080	PFN2	Profilin-2	37.9	1.253	0.005	17	13
P31946	YWHAB	14-3-3 protein beta/alpha	53.7	1.276	0.005	17	13
O43396	TXNL1	Thioredoxin-like protein 1	23.5	6.869	0.005	12	3
P00338	LDHA	L-lactate dehydrogenase A chain	62	1.297	0.006	17	13
Q9H008	LHPP	Phospholysine phosphohistidine inorganic pyrophosphate phosphatase	34.8	4.668	0.007	17	9
O95502	NPTXR	Neuronal pentraxin receptor	67	-1.321	0.008	17	13
Q9Y6R7	FCGBP	IgGfC-binding protein	50.6	1.523	0.008	17	13
Q9H7C9	AAMDC	Mth938 domain-containing protein	53.3	6.141	0.010	9	1
Q9H4F8	SMOC1	SPARC-related modular calcium-binding protein 1	35.3	1.406	0.010	17	13
Q99969	RARRES2	Retinoic acid receptor responder protein 2	74.2	1.189	0.011	17	13
Q13591	SEMA5A	Semaphorin-5A	7.9	-1.715	0.011	0	1
O15240	VGF	Neurosecretory protein VGF	63.4	-1.413	0.012	17	13
P09493	TPM1	Tropomyosin alpha-1 chain	25.7	1.726	0.012	1	0

Supplementary Table 2 | Differentially expressed proteins in cohort 2 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# control samples
P61981	YWHAG	14-3-3 protein gamma	58.3	4.816	0.012	17	10
Q9UBW5	BIN2	Bridging integrator 2	3.2	-1.851	0.013	0	1
Q9HD45	TM9SF3	Transmembrane 9 superfamily member 3	14.1	4.770	0.013	5	0
P29622	SERPINA4	Kallistatin	65.1	1.300	0.013	17	13
P47972	NPTX2	Neuronal pentraxin-2	43.9	-1.503	0.014	17	13
P17936	IGFBP3	Insulin-like growth factor-binding protein 3	44.7	1.317	0.016	17	13
P13521	SCG2	Secretogranin-2	52.2	-1.304	0.017	17	13
Q16787	LAMA3	Laminin subunit alpha-3	3.6	1.503	0.017	1	0
P02647	APOA1	Apolipoprotein A-I	78.3	1.581	0.017	17	13
P01011	SERPINA3	Alpha-1-antichymotrypsin	81.1	1.251	0.019	17	13
P01213	PDYN	Proenkephalin-B	42.9	-8.781	0.019	4	8
P14174	MIF	Macrophage migration inhibitory factor	20.9	1.268	0.019	17	13
P07195	LDHB	L-lactate dehydrogenase B chain	56.6	1.171	0.020	17	13
Q15459	SF3A1	Splicing factor 3A subunit 1	8.1	6.508	0.020	13	5
P02763	ORM1	Alpha-1-acid glycoprotein 1	41.3	5.683	0.022	16	9
P16152	CBR1	Carbonyl reductase [NADPH] 1	75.1	1.262	0.022	17	13
P12955	PEPD	Xaa-Pro dipeptidase	45	1.301	0.022	17	13
P50453	SERPINB9	Serpin B9	53.7	-5.718	0.023	7	11

Supplementary Table 2 | Differentially expressed proteins in cohort 2 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# control samples
P51665	PSMD7	26S proteasome non-ATPase regulatory subunit 7	7.4	1.515	0.023	1	0
Q99832	CCT7	T-complex protein 1 subunit eta	8.6	1.588	0.023	1	0
Q16539	MAPK14	Mitogen-activated protein kinase 14	5.1	-1.729	0.024	0	1
POC7U0	ELFN1	Protein ELFN1	4.6	-1.978	0.024	0	1
Q15818	NPTX1	Neuronal pentraxin-1	56.9	-1.193	0.024	17	13
Q01469	FABP5	Fatty acid-binding protein, epidermal	80.7	1.239	0.024	17	13
POC658	LINGO3	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3	20.4	-3.082	0.025	12	13
P10644	PRKAR1A	cAMP-dependent protein kinase type I-alpha regulatory subunit	36.5	2.061	0.026	1	0
Q9HC38	GLOD4	Glyoxalase domain-containing protein 4	52.7	1.185	0.026	17	13
Q15262	PTPRK	Receptor-type tyrosine-protein phosphatase kappa	16.9	-1.207	0.026	17	13
Q7Z7M8	B3GNT8	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	26.7	4.703	0.028	12	4
P10646	TFPI	Tissue factor pathway inhibitor	17.1	2.023	0.028	2	0
O15540	FABP7	Fatty acid-binding protein, brain	68.9	2.687	0.028	17	11
P30508	HLA-C	HLA class I histocompatibility antigen, Cw-12 alpha chain	59	-6.500	0.028	4	8
P01009	SERPINA1	Alpha-1-antitrypsin;Short peptide from AAT	72	2.543	0.029	17	13
Q9UHG2	PCSK1N	ProSAAS	68.5	-1.208	0.029	17	13
P61278	SST	Somatostatin	20.7	-2.235	0.029	2	5

Supplementary Table 2 | Differentially expressed proteins in cohort 2 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# control samples
Q14520	HABP2	Hyaluronan-binding protein 2	46.3	1.316	0.030	17	13
P59665	DEFA1	Neutrophil defensin 1	28.7	4.850	0.030	17	10
P02787	TF	Serotransferrin	83.4	1.799	0.030	17	13
P62937	PPIA	Peptidyl-prolyl cis-trans isomerase A	70.9	1.240	0.031	17	13
Q01151	CD83	CD83 antigen	4.9	1.590	0.031	1	0
P00558	PGK1	Phosphoglycerate kinase 1	77.5	1.256	0.033	17	13
A0A0C4DH73	IGKV1-12	Immunoglobulin kappa variable 1-12	13.7	-1.603	0.033	0	1
P0DP25	CALM3	Calmodulin-3	61.1	1.186	0.033	17	13
Q8WY21	SORCS1	VPS10 domain-containing receptor SorCS1	38.1	-1.273	0.034	17	13
Q7Z7G0	ABI3BP	Target of Nesh-SH3	22.2	1.233	0.035	17	13
CON_Q3MHN5			19,2	-1.465	0.035	0	1
P01008	SERPINC1	Antithrombin-III	71.8	1.239	0.035	17	13
Q96GD0	PDXP	Pyridoxal phosphate phosphatase	28.7	3.596	0.037	8	2
Q4LDE5	SVEP1	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1	9.5	3.207	0.037	11	4
P36980	CFHR2	Complement factor H-related protein 2	68.3	1.517	0.037	17	13
P13497	BMP1	Bone morphogenetic protein 1	9.3	3.890	0.038	15	7
P01042	KNG1	Kininogen-1	67.9	1.463	0.039	17	13

Supplementary Table 2 | Differentially expressed proteins in cohort 2 based on mass spectrometry data analysis (continued)

Uniprot Accession	Gene name	Protein name	Sequence coverage (%)	Fold change	p-value	# DLB samples	# control samples
Q9BZ76	CNTNAP3	Contactin-associated protein-like 3	30.4	-3.497	0.041	9	11
Q08554	DSC1	Desmocollin-1	24.6	2.691	0.042	17	11
P0C0L5	C4B	Complement C4-B	80	1.219	0.044	17	13
P06744	GPI	Glucose-6-phosphate isomerase	44.4	1.250	0.044	17	13
Q6ZN30	BNC2	Zinc finger protein basonuclin-2	4.3	-21.430	0.044	7	10
P00568	AK1	Adenylate kinase isoenzyme 1	59.8	3.112	0.044	17	10
Q16853	AOC3	Membrane primary amine oxidase	19.8	-3.288	0.045	9	11
Q9UIW2	PLXNA1	Plexin-A1	19.5	-2.576	0.045	14	13
Q5BIV9	SPRN	Shadow of prion protein	22.5	3.455	0.045	6	1
Q14563	SEMA3A	Semaphorin-3A	27.8	-3.326	0.045	9	11
P27348	YWHAQ	14-3-3 protein theta	43.7	3.297	0.045	14	7
Q16473	TNXA	Putative tenascin-XA	62.4	-1.597	0.046	0	1
Q9ULB1	NRXN1	Neurexin-1	48.5	-1.171	0.046	17	13
P31150	GDI1	Rab GDP dissociation inhibitor alpha	69.4	1.205	0.046	17	13
Q9NZL9	MAT2B	Methionine adenosyltransferase 2 subunit beta	17.4	2.582	0.047	3	0
Q9HDC9	APMAP	Adipocyte plasma membrane-associated protein	28.4	2.333	0.047	3	0
Q9GZQ8	MAP1LC3B	Microtubule-associated proteins 1A/1B light chain 3B	27.2	6.112	0.048	12	5
P04899	GNAI2	Guanine nucleotide-binding protein G(i) subunit alpha-2	10.4	-1.871	0.049	0	1
P07307	ASGR2	Asialoglycoprotein receptor 2	33.8	-1.695	0.049	0	1
P49862	KLK7	Kallikrein-7	50.2	-4.699	0.049	10	12
P35612	ADD2	Beta-adducin	6.1	1.375	0.050	1	0

List of 93 differentially expressed proteins in CSF from patients with DLB compared to CSF from cognitively normal controls ($p < 0.05$). Proteins in bold ($n=60$) also fulfilled the predefined criteria for candidate biomarkers ($p < 0.05$, fold change > 1.2 , $> 20\%$ sequence coverage, detected in at least 50% of DLB patients or controls).

Supplementary Table 3 | Comprehensive overview of CSF studies of the identified candidate biomarkers for DLB

Study	Method	Participants	Results
Neurosecretory protein VGF (VGF)			
Brinkmalm (2018)¹	Targeted Mass Spectrometry (PRM-MS)	10 AD patients 13 healthy controls	VGF ↓ in AD vs controls
Carrette (2003)²	Quantitative Mass Spectrometry	9 AD 10 healthy controls	VGF ↓ in AD vs controls
Duits (2018)³	Targeted Mass Spectrometry (PRM-MS)	40 AD 40 MCI 40 non-demented controls	VGF ↓ in AD vs controls VGF ↑ in MCI vs AD
Hendrikson (2015)⁴	Targeted Mass Spectrometry (SRM)	30 AD 30 controls	VGF ↓ in AD vs controls
Holtta (2015)⁵	Quantitative Mass Spectrometry	8 AD 8 non-demented controls	VGF ↓ in AD vs controls
Jahn (2011)⁶	Quantitative Mass Spectrometry	34 AD 17 controls	VGF ↓ in AD vs controls
Llano (2017)⁷	Targeted Mass Spectrometry (MRM)	66 AD 135 MCI 86 normal aged controls	VGF ↓ in AD vs controls
Selle (2005)⁸	Quantitative Mass Spectrometry	127 AD 86 non-demented controls 66 non-AD demented patients	VGF ↓ in AD vs controls
Simonsen (2007)⁹	Quantitative Mass Spectrometry	85 AD 20 FTD 32 healthy controls	VGF ↓ in AD vs controls
Wijte (2012)¹⁰	Quantitative Mass Spectrometry	20 AD 20 non-demented controls NB. Postmortem CSF	VGF ↓ in AD vs controls

Supplementary Table 3 | Comprehensive overview of CSF studies of the identified candidate biomarkers for DLB (continued)


Study	Method	Participants	Results
Neurosecretory protein VGF (VGF)			
Ruetschi (2012)¹¹	Quantitative Mass Spectrometry	16 FTD 12 non-demented controls	VGF ₂₆₋₆₂ ↓ in FTD vs controls
Pasinetti (2006)¹²	Quantitative Mass Spectrometry	36 ALS 21 healthy controls	VGF ₃₉₈₋₄₁₁ ↓ in ALS vs controls
Zhao (2008)¹³	ELISA	17 ALS 21 healthy controls	VGF ₃₉₈₋₄₁₁ ↓ in ALS vs controls
Huang (2006)¹⁴	Quantitative Mass Spectrometry	41 Schizophrenia 40 healthy controls	VGF ₂₃₋₆₂ ↑ in schizophrenia vs controls
Secretogranin-2 (SCG2)			
Brinkmalm (2018)¹	Targeted Mass Spectrometry (PRM-MS)	10 AD patients 13 healthy controls	SCG2 ↓ in AD vs controls
Liano (2017)⁷	Targeted Mass Spectrometry (MIRM)	66 AD 86 normal aged controls	SCG2 ↓ in AD vs controls
Mattsson (2007)¹⁵	Quantitative Mass Spectrometry	46 MS 46 healthy siblings 50 healthy controls	SCG2 ↓ in MS vs siblings and controls
ProSAAS (PCSK1N)			
Abdi (2006)¹⁶	Quantitative Mass Spectrometry	10 AD 10 PD 5 DLB 10 normal aged controls	ProSAAS ↓ in AD vs controls No significant changes in DLB and PD
Jahn (2011)⁶	Quantitative Mass Spectrometry	34 AD 17 controls	ProSAAS ↓ in AD vs controls

Supplementary Table 3 | Comprehensive overview of CSF studies of the identified candidate biomarkers for DLB (continued)

Study	Method	Participants	Results
ProSAAS (PCSK1IN)			
Wang (2016)¹⁷	Quantitative Mass Spectrometry	8 AD 4 non-demented controls	ProSAAS ↓ in AD vs controls
Davidsson (2002)¹⁸	Quantitative Mass Spectrometry	15 FTD 12 non-demented controls	ProSAAS ↓ in FTD vs controls
Neuronal pentraxin-2 (NPTX2) and Neuronal pentraxin receptor (NPTXR)			
Hendrikson (2015)⁴	Targeted Mass Spectrometry (SRM)	30 AD 30 controls	NPTXR ↓ in AD vs controls
Liano (2017)⁷	Targeted Mass Spectrometry (MRM)	66 AD 135 MCI 86 normal aged controls	NPTX2 and NPTXR ↓ in AD vs controls NPTX2 and NPTXR ↓ in MCI converters vs non-converters
Perrin (2011)¹⁹	Quantitative Mass Spectrometry	24 AD 24 non-demented controls	NPTXR ↓ in AD vs controls
Spellman (2015)²⁰	Targeted Mass Spectrometry (MRM)	66 AD 134 MCI 85 healthy controls	NPTX2 and NPTXR ↓ in AD vs controls
Xiao (2017)²¹	ELISA and Westernblot	30 AD 36 healthy controls	NPTX2 and NPTXR ↓ in AD vs controls
Proenkephalin-B (PDYN)			
Liano (2017)⁷	Targeted Mass Spectrometry (MRM)	66 AD 135 MCI 86 normal aged controls	PDYN ↓ in AD vs controls

Table lists CSF studies of the six identified candidate biomarkers for DLB in neurological and psychiatric diseases. Abbreviations: AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; DLB, dementia with Lewy bodies; FTD, Frontotemporal dementia; MRM, Multiple reaction monitoring; MS, Multiple sclerosis; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor; PCSK1IN, ProSAAS; PRM-MS, Parallel Reaction Monitoring Mass Spectrometry; PDYN, Proenkephalin-B; SGG2, Scretogranin-2; SRM, Selected Reaction Monitoring; VGF, Neurosecretory protein VGF.

Supplementary Figure 1 | K-means cluster plot of identified clusters



Cluster solution was plotted against the first two dimensions. The symbols represent the clinical diagnosis (circle = DLB; triangle = Control; plus = FTD, cross = PD, diamond = AD). The colors represent the four different clusters. Abbreviations: AD, Alzheimer's disease; DLB, dementia with Lewy bodies; FTD, Frontotemporal dementia; PD, Parkinson's disease.

REFERENCES SUPPLEMENTARY TABLE 3

1. Brinkmalm G, Sjodin S, Simonsen AH, et al. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. *Proteomics Clin Appl*. 2018 Jan;12(1).
2. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. *Proteomics*. 2003 Aug;3(8):1486-94.
3. Duits FH, Brinkmalm G, Teunissen CE, et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. *Alzheimers Res Ther*. 2018 Jan 15;10(1):5.
4. Hendrickson RC, Lee AY, Song Q, et al. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid. *PLoS One*. 2015;10(8):e0135365.
5. Holtta M, Minthon L, Hansson O, et al. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. *J Proteome Res*. 2015 Feb 6;14(2):654-63.
6. Jahn H, Wittke S, Zurbig P, et al. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. *PLoS One*. 2011;6(10):e26540.
7. Llano DA, Bundela S, Mudar RA, Devanarayan V, Alzheimer's Disease Neuroimaging I. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. *PLoS One*. 2017;12(8):e0182098.
8. Selle H, Lamerz J, Buerger K, et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. *Comb Chem High Throughput Screen*. 2005 Dec;8(8):801-6.
9. Simonsen AH, McGuire J, Podust VN, et al. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. *Dement Geriatr Cogn Disord*. 2007;24(6):434-40.
10. Wijte D, McDonnell LA, Balog CI, et al. A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. *Methods*. 2012 Apr;56(4):500-7.
11. Ruetschi U, Zetterberg H, Podust VN, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. *Exp Neurol*. 2005 Dec;196(2):273-81.
12. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. *Neurology*. 2006 Apr 25;66(8):1218-22.
13. Zhao Z, Lange DJ, Ho L, et al. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. *Int J Med Sci*. 2008 Apr 15;5(2):92-9.
14. Huang JT, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. *PLoS Med*. 2006 Nov;3(11):e428.
15. Mattsson N, Ruetschi U, Podust VN, et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. *J Neurochem*. 2007 Dec;103(5):1932-9.

16. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. *J Alzheimers Dis.* 2006 Aug;9(3):293-348.
17. Wang J, Cunningham R, Zetterberg H, et al. Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. *Proteomics Clin Appl.* 2016 Dec;10(12):1225-41.
18. Davidsson P, Sjogren M, Andreasen N, et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. *Brain Res Mol Brain Res.* 2002 Dec 30;109(1-2):128-33.
19. Perrin RJ, Craig-Schapiro R, Malone JP, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. *PLoS One.* 2011 Jan 12;6(1):e16032.
20. Spellman DS, Wildsmith KR, Honigberg LA, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. *Proteomics Clin Appl.* 2015 Aug;9(7-8):715-31.
21. Xiao MF, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in Alzheimer's Disease. *Elife.* 2017 Mar 23;6.

